2011结直肠癌更新课件.pptVIP

* * CRC; colorectal cancer; HR, hazard ratio; PFS, progression-free survival * * * EGFR signaling Is mainly dependent on an intact KRAS pathway in CRC. In 40% of the patients, KRAS is mutated , leading to constitutive activation of the pathway and therefore will interfere withEGFR blockade. …… Not all tumors with an intact KRAS pathway will respond to anti-EGFR blockade. There is the possibility that other mutations downstream from KRAS , such as BRAF ( 5-10%) of patients or in other parallel pathways may interfere with EGFR blockade. * * * * SPEAKER NOTES The large, phase III randomized trial, VELOUR, has enrolled 1226 patients with previously treated metastatic CRC whose disease progressed on an oxaliplatin-based regimen. Patients are randomized to receive either aflibercept plus FOLFIRI or FOLFIRI alone. An important stratification in this trial is patients who have received prior bevacizumab-containing therapy in the front-line setting. In the United States, the majority of patients receive bevacizumab-containing therapy as treatment for their newly diagnosed mCRC. VELOUR has completed accrual of patients. The primary endpoint in this trial is median OS. An interim analysis of the data from VELOUR determined that the trial should continue to final analysis of OS. Final results are expected in late 2011. More details on this trial are available at clinicaltrials.gov (NC. * * SPEAKER NOTES The large, phase III randomized trial, VELOUR, has enrolled 1226 patients with previously treated metastatic CRC whose disease progressed on an oxaliplatin-based regimen. Patients are randomized to receive either aflibercept plus FOLFIRI or FOLFIRI alone. An important stratification in this trial is patients who have received prior bevacizumab-containing therapy in the front-line setting. In the United States, the majority of patients receive bevacizumab-containing therapy as treatment for their newly diagnosed mCRC. VELOUR has completed accrual of patients. The p